NanoVibronix, Inc. (NASDAQ:NAOV – Get Rating) was the target of a large decline in short interest in the month of April. As of April 30th, there was short interest totalling 416,000 shares, a decline of 40.9% from the April 15th total of 703,600 shares. Based on an average trading volume of 1,450,000 shares, the days-to-cover ratio is currently 0.3 days.
Shares of NanoVibronix stock traded up $0.09 during trading on Friday, reaching $0.64. The company’s stock had a trading volume of 879,803 shares, compared to its average volume of 169,576. The company has a 50-day moving average price of $0.81 and a two-hundred day moving average price of $0.96. NanoVibronix has a fifty-two week low of $0.48 and a fifty-two week high of $4.19.
Institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. increased its stake in NanoVibronix by 53.7% in the 1st quarter. Vanguard Group Inc. now owns 651,262 shares of the company’s stock valued at $755,000 after buying an additional 227,454 shares during the period. Renaissance Technologies LLC acquired a new position in NanoVibronix in the 4th quarter valued at $361,000. Amtrust Financial Services Inc. increased its stake in NanoVibronix by 69.8% in the 4th quarter. Amtrust Financial Services Inc. now owns 248,148 shares of the company’s stock valued at $258,000 after buying an additional 102,000 shares during the period. Geode Capital Management LLC increased its stake in NanoVibronix by 46.7% in the 3rd quarter. Geode Capital Management LLC now owns 200,752 shares of the company’s stock valued at $413,000 after buying an additional 63,868 shares during the period. Finally, Two Sigma Investments LP acquired a new position in NanoVibronix in the 3rd quarter valued at $333,000. 6.80% of the stock is currently owned by institutional investors and hedge funds.
NanoVibronix, Inc, through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its principal products include UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device, which facilitates tissue regeneration and wound healing.
- Get a free copy of the StockNews.com research report on NanoVibronix (NAOV)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for NanoVibronix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoVibronix and related companies with MarketBeat.com's FREE daily email newsletter.